Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00977769
Other study ID # 2009carb
Secondary ID
Status Completed
Phase Phase 4
First received September 15, 2009
Last updated April 4, 2014
Start date November 2009
Est. completion date October 2011

Study information

Verified date April 2014
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority Norway: Norwegian Medicines Agency
Study type Interventional

Clinical Trial Summary

A randomized double-blind trial of oxytocin 5 u, carbetocin 100 µg and placebo with hemodynamic response as a primary outcome measure.


Description:

Healthy pregnant women sheduled for elective cesarean section. Invasive hemodynmaic monitoring with LiDCO Plus.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date October 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy pregnant women for planned cesarean section

Exclusion Criteria:

- Bleeding disorders

- Placenta disorders

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Effects of; Anesthesia, in Pregnancy

Intervention

Drug:
carbetocin 100 µg
Hemodynamic effect of
oxytocin 5 u
Hemodynamic effect of
placebo (NaCl)
Hemodynamic effect of

Locations

Country Name City State
Norway Division of Anaesthesia and Intensive Care Medicine, Oslo University Hospital - Rikshospitalet Oslo
Norway Division of Anesthesia and Intensive Care Medicine Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

References & Publications (1)

Rosseland LA, Hauge TH, Grindheim G, Stubhaug A, Langesæter E. Changes in blood pressure and cardiac output during cesarean delivery: the effects of oxytocin and carbetocin compared with placebo. Anesthesiology. 2013 Sep;119(3):541-51. doi: 10.1097/ALN.0b — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac Output The relative change in CO from baseline at the time of delivery up to 2.5 minutes post delivery. 2.5 minutes Yes
Primary Arterial Blood Pressure The mean change in SAP compared with baseline at the time of delivery up to 2.5 minutes post delivery. 2.5 min Yes
Secondary Bleeding The calculated estimated blood loss from delivery until 2 h after intervention 120 minutes Yes